Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity has been approved for AMA PRA Category 1 Credit™.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669.
This activity is supported by educational grants from Acerta Pharma – A member of the AstraZeneca Group, Celgene Corporation, Daiichi Sankyo, Inc., Jazz Pharmaceuticals, Inc., NewLink Genetics, and Novartis Pharmaceuticals Corporation.
Now in its 23rd year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma provides practitioners who manage hematologic malignancies the practical tools to translate emerging data into the best therapy for patients with these tumors, personalize care based upon patient and tumor characteristics, and apply novel management strategies to their practices to improve outcomes for their patients.
Back by popular demand! This 3.5-day meeting will be held from Thursday through mid-afternoon Sunday. As always, agenda topics will focus on methods to apply state-of-the-art strategies to your clinical practice settings. This engaging and highly interactive meeting will provide ample opportunity to interact with internationally renowned experts in the management of leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, and benign hematologic malignancies. Our faculty will distill practice-changing evidence and recommend methods to place this information in its proper clinical context so it can be applied to the real-world care scenarios you encounter. In doing so, a focus will be placed on how to proactively mitigate and manage treatment-related toxicities associated with new treatment strategies.
The well-known and highly interactive Medical Crossfire® discussion panels interspersed throughout the meeting will allow attendees to explore some of the most challenging clinical situations in the management of hematologic malignancies, many of which have multiple potential approaches to care.
This dynamic Congress will challenge participants to apply new information they have learned, reflect on new practices they can bring back to their clinics to share with their peers, and ultimately improve patient outcomes in their practice settings.
This activity is supported by educational grants from Acerta Pharma – A member of the AstraZeneca Group, Celgene Corporation, Daiichi Sankyo, Inc., Jazz Pharmaceuticals, Inc., NewLink Genetics, Novartis Pharmaceuticals Corporation.
This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies may also participate.
Dec 31, 2018
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor Types
Dec 31, 2018
Dec 31, 2018